Table 2 Percent (%) biosimilar share of reference product sales [14],[39]
From: Potential impact of subsequent entry biologics in nephrology practice in Canada
| Â | Percent (%) biosimilar share of reference product sales | Â | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | Austria | France | Germany | Italy | Poland | Spain | Sweden | UK | EU total |
Epoetin | 50 | 11 | 65 | 7 | 62 | 16 | 63 | 9 | 18 |
Filgrastim | 52 | 42 | 45 | 18 | 38 | 24 | 45 | 80 | 38 |
Somatropin | 6 | 20 | 12 | 12 | 7 | 15 | 21 | 4 | 13 |
Infliximab | Approved but not yet marketed | Â | |||||||